pembrolizumab,Talabostat
merck,BioXcel Therapeutics
['gu ', 'pembro', 'crpc', 'pcsm', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
talabostat and pembrolizumab showed antitumor activity in mcrpc patients with scnc phenotype in a phase 2a study presented at asco gu 2023. #gu23 #pcsm 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.